What is SparingVision?
SparingVision is a genomic medicines company dedicated to developing transformative therapies for vision-threatening conditions. By leveraging cutting-edge genomic science, the company aims to address significant unmet needs in ophthalmology, positioning itself at the forefront of innovation in the rare disease and vision care sectors. The substantial capital raised indicates strong investor confidence in its scientific approach and therapeutic pipeline.
How much funding has SparingVision raised?
SparingVision has raised a total of $130.5M across 3 funding rounds:
Grant
$2.8M
Series A
$52.7M
Series B
$75M
Grant (2019): $2.8M with participation from European EIC Accelerator
Series A (2020): $52.7M led by Bpifrance, Jeito Capital, University of Pittsburgh Medical Centre Enterprise, 4BIO Capital, Ysios Capital, and Foundation Fighting Blindness
Series B (2022): $75M supported by Jeito, Bpifrance, University of Pittsburgh Medical Center Enterprise, 4BIO Capital, Ysios Capital, and Retinal Degeneration Fund
Key Investors in SparingVision
Jeito
Jeito Capital is a global investment firm focused on patient benefit-driven medical innovation, providing significant capital to accelerate the growth of groundbreaking companies in therapeutic areas.
Bpifrance
Bpifrance is a French public investment bank that finances companies at all stages of development, supporting innovation, international expansion, and export activities.
4BIO Capital
4BIO Capital is a London-based venture capital firm specializing in life sciences, with a focus on advanced therapies addressing significant unmet medical needs, including gene and cell therapies.
What's next for SparingVision?
The recent major strategic investment signals a pivotal growth phase for SparingVision. This capital infusion is expected to accelerate the advancement of its genomic medicine programs through clinical development and towards market readiness. The company's focus on vision-saving treatments, supported by enterprise-level backing, suggests a strategic expansion of its research and development capabilities, potentially including new therapeutic targets and broader patient access initiatives. This financing round is crucial for solidifying its market position and achieving its mission of delivering life-changing therapies.
See full SparingVision company page
